[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Madrigal Pharmaceuticals Inc (MDGL)

Madrigal Pharmaceuticals Inc (MDGL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Madrigal's Rezdiffra Revenue Momentum May Already Be Reflecting a Best-Case Scenario That Hasn't Arrived

Madrigal Pharmaceuticals Inc (MDGL) reports Q2 2026 earnings tomorrow, July 30, before market open, with analysts expecting a loss of $-2.55 per share. The central question is whether the company's flagship MASH treatment Rezdiffra can continue its commercial momentum and narrow losses faster than expected. With the stock up 8% year-to-date and trading near $547, investors will scrutinize revenue trajectory and guidance as MDGL navigates the critical early commercialization phase of its first approved product.

Madrigal Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies for metabolic and liver diseases, with its lead product Rezdiffra (resmetirom) approved for treating metabolic dysfunction-associated steatohepatitis...

Fundamentals

See More
  • Market Capitalization, $K 12,608,860
  • Shares Outstanding, K 23,056
  • Annual Sales, $ 958,400 K
  • Annual Income, $ -288,280 K
  • EBIT $ -314 M
  • EBITDA $ -307 M
  • 60-Month Beta -1.05
  • Price/Sales 12.96
  • Price/Cash Flow N/A
  • Price/Book 22.84

Options Overview Details

View History
  • Implied Volatility 44.59% (-13.32%)
  • Historical Volatility 43.77%
  • IV Percentile 8%
  • IV Rank 21.71%
  • IV High 73.99% on 11/03/25
  • IV Low 36.43% on 05/06/26
  • Expected Move (DTE 21) 38.39 (7.79%)
  • Put/Call Vol Ratio 1.05
  • Today's Volume 1,783
  • Volume Avg (30-Day) 316
  • Put/Call OI Ratio 0.46
  • Today's Open Interest 11,217
  • Open Int (30-Day) 14,869
  • Expected Range 454.72 to 531.50

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-1.25
  • Number of Estimates 6
  • High Estimate $-0.97
  • Low Estimate $-1.63
  • Prior Year $-5.08
  • Growth Rate Est. (year over year) +75.39%

Price Performance

See More
Period Period Low Period High Performance
1-Month
447.01 +10.31%
on 07/30/26
569.44 -13.40%
on 07/09/26
-43.84 (-8.16%)
since 06/30/26
3-Month
445.20 +10.76%
on 06/03/26
569.44 -13.40%
on 07/09/26
-24.28 (-4.69%)
since 04/30/26
52-Week
290.00 +70.04%
on 07/31/25
615.00 -19.82%
on 12/24/25
+203.23 (+70.11%)
since 07/30/25

Most Recent Stories

More News
Madrigal: Q2 Earnings Snapshot

Madrigal: Q2 Earnings Snapshot

MDGL : 493.11 (-9.83%)
Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates

Second-quarter 2026 Rezdiffra ® (resmetirom) net sales of $364.3 million, representing year-over-year growth of 71% As of June 30, 2026, more than 49,000 patients on Rezdiffra, more...

MDGL : 493.11 (-9.83%)
Madrigal's Rezdiffra Revenue Momentum May Already Be Reflecting a Best-Case Scenario That Hasn't Arrived

Barchart Research What to Expect from MDGL Earnings MDGL Generated July 29, 2026 Current Price $546.88 EPS Estimate $$-2.55 Consensus Rating Strong Buy Average Move 10.51% Madrigal's Rezdiffra Revenue...

MDGL : 493.11 (-9.83%)
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated...

MDGL : 493.11 (-9.83%)
Madrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026

CONSHOHOCKEN, Pa., July 16, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its second-quarter 2026 financial results on Thursday, July 30,...

MDGL : 493.11 (-9.83%)
Madrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP Portfolio

Received two new U.S. Rezdiffra ® (resmetirom) patents in F2/F3; both patents will be listed in the FDA’s Orange Book Received new U.S. resmetirom patent directed to a method of administering...

MDGL : 493.11 (-9.83%)
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., July 06, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated...

MDGL : 493.11 (-9.83%)
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., June 22, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated...

MDGL : 493.11 (-9.83%)
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., June 04, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated...

MDGL : 493.11 (-9.83%)
Madrigal Pharmaceuticals to Participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026

CONSHOHOCKEN, Pa., June 03, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the 47 th Annual Global Goldman Sachs Health Care...

MDGL : 493.11 (-9.83%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakest short term outlook on maintaining the current direction.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Madrigal Pharmaceuticals, Inc. is engaged in developing small-molecule drugs addressing cardiovascular and metabolic diseases. Its products pipeline include MGL-3196, an orally administered liver-directed thyroid hormone receptor-' agonist that is used for the treatment of NASH, dyslipidemia/hypercholesterolemia...

See More

Key Turning Points

3rd Resistance Point 583.64
2nd Resistance Point 547.10
1st Resistance Point 520.10
Last Price 493.11
1st Support Level 456.56
2nd Support Level 420.02
3rd Support Level 393.02

See More

52-Week High 615.00
Last Price 493.11
Fibonacci 61.8% 490.85
Fibonacci 50% 452.50
Fibonacci 38.2% 414.15
52-Week Low 290.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.